創薬流通市場「薬市楽座」

安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。

創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。

なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。

創薬シーズ・創薬技術一覧(PDF) 疾患領域別 創薬シーズ一覧(PDF) 創薬シーズ・創薬技術一覧(Excel)

絞り込み検索

掲載日 シーズ番号 作用機序 適応症 投与経路 モダリティ 開発ステージ 備考
20/11/25 GEM228 GLP-1 with fatty acids bundles Type2 Diabetes, obesity; NASH s.c. Peptide conjugated fatty acid
Preclinical GEM228
-can be produced in high quality.
-can lower blood glucose better than semaglutide and effectively control blood glucose level at 10 nmol/kg
- can effectively reduce body weight and reduce liver fat
問合せ
20/11/25 GEM227 Octreotide with fatty acids bundles carcinoid syndrome/ acromegaly s.c. Peptide conjugated fatty acid
Preclinical GEM227
- can be produced in high quality and bind to HSA effectively.
- Fatty acids bundle can effectively prolong serum half-life of octreotide and antiproliferative effect of GEM227 is similar to that of octreotide.
- can effectively reduce serotonin level in xenograft mouse model.
問合せ
20/11/25 GEM226 Anti-fibrin scFv with reteplase Pathological Clots i.v. Antibody conjugated reteplase
Preclinical GEM226
- can bind to human fibrin/crosslinked fibrin, but not to fibrinogen and bind to human fibrin under high concentration of fibrinogen.
-GEM226 is stable in buffer at 4°C and alteplase showed similar enzyme kinetics to tPA substrate, also can dissolve clots effectively, accumulate at the clot in vivo and bind to human clots specifically
-GEM226 has better PK profile in rat and shows better clot-dissolving effect than that of alteplase in MCAO mice model.
-GEM226-treated MCAO stroke mice have better neurobehavior than the mice treated with alteplase
問合せ
20/11/24 GEM225 Regulating the cellular pathway that differentiates cancer cells, leading to apoptosis and cancer arrest Triple negative breast cancer, Pancreatic cancer i.v. Protein
Preclinical - GEM225 is a recombinant human KL-1 (rhKL-1).
- KL-1 is the domain with the anti-cancer activity of Klotho, a hormone with tumor suppression activity.
- Klotho expression in epigenetically silenced in malignant tissues.
- rhKL-1 inhibited tumor growth in-vivo.
- rhKL-1 demonstrated acceptable safety profile in the in-vivo studies.
- rhKL-1 can provide effective and safe solution where currently approved treatments fail.
問合せ
20/10/15 GEM223 Regulation of cellular phosphate handling and intracellular energy status Hyperphospha-temia in chronic kidney disease (CKD) Chemotherapy-induced hyperphospha-temia   (Tumor Lysis Syndrome, TLS) Oral Intra-venous Small molecule Pre-IND First-in-class drug with a new MOA that is completely different from those of existing drugs for the treatment of hyperphosphatemia in CKD and TLS, a serious complication in cancer patients.
- A unique and highly effective mechanism to reduce blood phosphate levels in mammals
- Once-daily dosing potential
- No gastrointestinal side-effects
- Mechanism-based kidney protective effects
- IND-enabling 4-week toxicological studies have been finished
問合せ
20/09/18 GEM222 Anti-Podoplanin Antibody Osteosarcoma, Lung squamous cell carcinoma, Soft tissue sarcoma, thrombosis Injection Antibody Preclinical - First-in-Class humanized Anti-Podoplanin Antibody
- Podoplanin is a transmembrane protein. It is found to induce platelet aggregation and express in various malignant tumor cells, and involve in proliferation of these tumor cells.
- GEM222 suppressed tumor growth and metastasis in human osteosarcoma and human lung squamous cell carcinomas xenografted in immunodeficient mouse.
- No side effect was observed in preliminary monkey study.
問合せ
20/09/08 GEM221 Anti-Globo H ADC Cancer i.v. Antibody Preclinical High affinity, fast internalization, good in vitro cytotoxicity
- Showed great tumor growth inhibition (>90%, 3 mg/kg) in HCC-1428 animal models without any body weight loss
- Can be prepared reproducibly at gram scale.
問合せ
20/09/08 GEM220 Anti-Globo H Antibody Breast Cancer i.v. Antibody *Preclinical **Discovery * Anti-Globo H monolonal antibody
- Higher patient population in breast cancer (61%).
- Anti-cancer efficacy demonstrated in breast cancer animal model through ADCC and CDC.
**Anti-Globo H bispecific antibody
- High correct pairing (>95%)
-Target cell-dependent T cell activation (Better safety profile).
- Anti-cancer efficacy demonstrated in breast cancer animal model through T cell-mediated cytotoxicity.
問合せ
20/09/08 GEM219 Anti-TIM-3 antibody Cancer i.v. Antibody Preclinical GEM219 is a fully human anti-TIM-3 antibody with high affinity in vitro and cell-based binding assay.
- The anti-TIM-3 antibodies are also highly functional in cellbased bioassay.
- Some anti-TIM-3 antibodies have cross-species recognition ability to mouse TIM-3.
- Animal efficacy studies are in progress
問合せ
20/09/08 GEM218 Anti- Human PD-L1 antibodies Cancer i.v. Antibody Preclinical GEM218 is a novel monoclonal antibody that specifically binds to PD-L1 with high affinity and effectively blocks PD-1/PD-L1 interaction.
- Can be well detected by the PD-1/PD-L1 Blockade Assay.
- Novel binding epitopes.
- Good potential for a companion diagnosis.
- The efficacy and toxicity are studied in various in vitro and in vivo models
問合せ